Here are the DEF 14A proxy statements from Dianthus Therapeutics, Inc. (DNTH) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow DNTH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DNTH filings page.
Dianthus Therapeutics, Inc. is calling a virtual 2026 annual stockholders meeting on May 21, 2026 at 9:00 a.m. Eastern Time. Holders of 54,448,771 common shares of record on March 30, 2026 may vote online after registering at the meeting website.
Stockholders will elect three Class II directors to serve until 2029, cast an advisory vote on executive compensation, and ratify Deloitte & Touche LLP as independent auditor for 2026. The proxy details a staggered, largely independent board, committee structures, director pay in cash and stock options, and performance-based executive pay tied to drug development milestones and a reported 649% total stockholder return since the 2023 reverse merger.